Hepatitis C Virus: No Longer a Barrier to Oncology Care

Sobia N. Laique, Hugo E Vargas

Research output: Contribution to journalArticle

Abstract

Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.

Original languageEnglish (US)
Pages (from-to)207-208
Number of pages2
JournalThe American Journal of Gastroenterology
Volume114
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Hepacivirus
Medical Oncology
Virus Diseases
Antiviral Agents
Clinical Trials
Neoplasms
Therapeutics
Sustained Virologic Response

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Hepatitis C Virus : No Longer a Barrier to Oncology Care. / Laique, Sobia N.; Vargas, Hugo E.

In: The American Journal of Gastroenterology, Vol. 114, No. 2, 01.02.2019, p. 207-208.

Research output: Contribution to journalArticle

@article{ceb65f003ba341f88ec5849aa353d3e9,
title = "Hepatitis C Virus: No Longer a Barrier to Oncology Care",
abstract = "Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95{\%} sustained virologic response) and safely cured.",
author = "Laique, {Sobia N.} and Vargas, {Hugo E}",
year = "2019",
month = "2",
day = "1",
doi = "10.14309/ajg.0000000000000095",
language = "English (US)",
volume = "114",
pages = "207--208",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Hepatitis C Virus

T2 - No Longer a Barrier to Oncology Care

AU - Laique, Sobia N.

AU - Vargas, Hugo E

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.

AB - Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.

UR - http://www.scopus.com/inward/record.url?scp=85061147130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061147130&partnerID=8YFLogxK

U2 - 10.14309/ajg.0000000000000095

DO - 10.14309/ajg.0000000000000095

M3 - Article

C2 - 30676362

AN - SCOPUS:85061147130

VL - 114

SP - 207

EP - 208

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -